Market Report, "Argentina Pharmaceuticals & Healthcare Report Q3 2013", published

From: Fast Market Research, Inc.
Published: Sun Jun 16 2013

High inflation has undermined foreign drugmakers' profitability in Argentina's pharmaceutical market. The potential currency devaluation will further erode the returns of foreign investment. Nevertheless, some multinationals continue to invest in the country, as its market size, relatively welldeveloped local manufacturing force and its strategic location mean Argentina remains an appealing prospect..

Headline Expenditure Projections:

Pharmaceuticals: ARS39.4bn (US$8.7bn) in 2012 to ARS49.4bn (US$8.9bn) in 2013; +25.3% in local currency terms and 2.7% in US dollar terms. The forecast figures remain the same as in Q213.

Healthcare: ARS198.7bn (US$43.7bn) in 2012 to ARS248.5bn (US$44.8bn) in 2013; +25.1% in local currency terms and +2.5% in US dollar terms. The forecast figures remain the same as in Q213.

Risk/Reward Rating: Argentina scores 59.3 in BMI's Pharmaceutical and Healthcare Risk/Reward Rating (RRR), making it the fourth most attractive pharmaceutical market in America. We have re-weighting the RRR components to improve the tool, and the adjusted scores for all markets in the Pharmaceuticals & Healthcare reports. Argentina's pharmaceutical market is expected to grow at double-digit rates through to 2016 in local currency terms, largely due to inflation.

Full Report Details at

Key Trends And Developments

* In Q113, ANMAT approved once daily Aubagio (teriflunomide) 14mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis (MS); abatacept for the treatment of adults with moderate-to-severe rheumatoid arthritis and Kombiglyze XR (saxagliptin + metformin HCl extendedrelease) for the treatment of type 2 diabetes.
* In March 2013, GlaxoSmithKline (GSK) invested a total of US$123mn to establish a new quality control and production site at Phoenix, an Argentinean subsidiary GSK acquired in mid-2010. The project aims to develop and produce high quality, affordable medicines for Argentina's and other Latin American pharmaceutical markets.
* In February 2013, Merck Sharp & Dohme (MSD; a subsidiary of the US-based multinational pharmaceutical company Merck & Co) signed a trade agreement with local drugmaker Laboratorios Bago to promote its products used in the country's primary care system..

BMI Economic View: We forecast that the marked slowing in the Argentine economy will continue this year, with real GDP growth falling to 1.6% from our estimate of 2.0% in 2012, as a currency devaluation pushes inflation higher, weighing on consumer and government spending, and liberalised import policies result in a greater net export drag on real GDP growth. That said, we forecast that base effects and greater competitiveness will boost real GDP growth to 3.0% next year.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q3 2013
- Australia Pharmaceuticals & Healthcare Report Q3 2013
- Mexico Pharmaceuticals & Healthcare Report Q3 2013
- Kenya Pharmaceuticals & Healthcare Report Q3 2013
- Pakistan Pharmaceuticals & Healthcare Report Q3 2013

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »